Other compounds potentially target the Hippo pathway for GC treatment: Tyrosine kinase inhibitors, such as dasatinib and pazopanib, have been shown to elicit phosphorylation and degradation of YAP1/TAZ for their cytoplasmic sequestration [150]. This evidence concerns the gene YAP1 and gastric cancer.